Your browser doesn't support javascript.
loading
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira, A; Masliah-Planchon, J; Callens, C; Vacher, S; Lecerf, C; Frelaut, M; Borcoman, E; Torossian, N; Ricci, F; Hescot, S; Sablin, M P; Tresca, P; Loirat, D; Melaabi, S; Trabelsi-Grati, O; Pierron, G; Gentien, D; Bernard, V; Vincent Salomon, A; Servant, N; Bieche, I; Le Tourneau, C; Kamal, M.
  • Moreira A; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: aurelie.moreira@curie.fr.
  • Masliah-Planchon J; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: julien.masliahplanchon@curie.fr.
  • Callens C; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: celine.callens@curie.fr.
  • Vacher S; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: sophie.vacher@curie.fr.
  • Lecerf C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: charlotte.lecerf@curie.fr.
  • Frelaut M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: maxime.frelaut@curie.fr.
  • Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: edith.borcoman@curie.fr.
  • Torossian N; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: nouritza.torossian@curie.fr.
  • Ricci F; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: francesco.ricci@curie.fr.
  • Hescot S; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: segolene.hescot@curie.fr.
  • Sablin MP; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: mariepaule.sablin@curie.fr.
  • Tresca P; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: patricia.tresca@curie.fr.
  • Loirat D; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: delphine.loirat@curie.fr.
  • Melaabi S; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: samia.melaabi@curie.fr.
  • Trabelsi-Grati O; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: olfa.trabelsigrati@curie.fr.
  • Pierron G; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: gaelle.pierron@curie.fr.
  • Gentien D; Department of Translational Research, Institut Curie, PSL Research University, Paris, France. Electronic address: david.gentien@curie.fr.
  • Bernard V; Department of Genetics, Institut Curie, PSL Research University, Paris, France. Electronic address: Virginie.Bernard@curie.fr.
  • Vincent Salomon A; Department of Pathology, Institut Curie, PSL Research University, Paris, France. Electronic address: anne.salomon@curie.fr.
  • Servant N; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France. Electronic address: nicolas.servant@curie.fr.
  • Bieche I; Department of Genetics, Institut Curie, PSL Research University, Paris, France; INSERM U1016 Research Unit, Cochin Institute, Paris, France. Electronic address: ivan.bieche@curie.fr.
  • Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France; INSERM U900, Institut Curie, Mines Paris Tech, Paris, France; Paris-Saclay University, Paris, France. Electronic address: christophe.letourneau@curie.fr.
  • Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, Saint-Cloud, France. Electronic address: maud.kamal@curie.fr.
Eur J Cancer ; 121: 202-209, 2019 11.
Article en En | MEDLINE | ID: mdl-31593830
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Algoritmos / Ensayos Clínicos Controlados Aleatorios como Asunto / Aprobación de Drogas / Terapia Molecular Dirigida / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Ejes tematicos: Pesquisa_clinica Banco de datos: MEDLINE Asunto principal: Algoritmos / Ensayos Clínicos Controlados Aleatorios como Asunto / Aprobación de Drogas / Terapia Molecular Dirigida / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article